Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Cirrhosis

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 54 articles:
HTML format
Text format



Single Articles


    May 2018
  1. TAJIRI K, Tokimitsu Y, Ito H, Atarashi Y, et al
    Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Dig Dis. 2018 May 31:1-8. doi: 10.1159/000489258.
    PubMed     Text format     Abstract available


    January 2018
  2. HUANG XW, Liao B, Huang Y, Liang JY, et al
    Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable?
    Dig Dis. 2018 Jan 19. pii: 000486196. doi: 10.1159/000486196.
    PubMed     Text format     Abstract available


  3. BAI L, Jin W, Kong M, Zhang X, et al
    Injury Resistance in the Setting of Liver Fibrosis Is Accompanied by the Inhibition of High-Mobility Group Box-1 Translocation and Release.
    Dig Dis. 2018;36:167-176.
    PubMed     Text format     Abstract available


    November 2017
  4. SHI L, Zhang X, Li J, Bai X, et al
    Favorable Effects of Endoscopic Ligation Combined with Drugs on Rebleeding and Mortality in Cirrhotic Patients: A Network Meta-Analysis.
    Dig Dis. 2017 Nov 21. doi: 10.1159/000484082.
    PubMed     Text format     Abstract available


    March 2017
  5. DI PASCOLI M, Ceranto E, De Nardi P, Donato D, et al
    Hospitalizations Due to Cirrhosis: Clinical Aspects in a Large Cohort of Italian Patients and Cost Analysis Report.
    Dig Dis. 2017 Mar 1. doi: 10.1159/000458722.
    PubMed     Text format     Abstract available


    January 2017
  6. POSE E, Cardenas A
    Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention.
    Dig Dis. 2017;35:402-410.
    PubMed     Text format     Abstract available


  7. HEGADE VS, Jones DE, Hirschfield GM
    Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
    Dig Dis. 2017;35:267-274.
    PubMed     Text format     Abstract available


  8. WONG LL, Hegade VS, Jones DEJ
    What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Dig Dis. 2017;35:359-366.
    PubMed     Text format     Abstract available


  9. IREDALE JP, Pellicoro A, Fallowfield JA
    Liver Fibrosis: Understanding the Dynamics of Bidirectional Wound Repair to Inform the Design of Markers and Therapies.
    Dig Dis. 2017;35:310-313.
    PubMed     Text format     Abstract available


  10. KOBAYASHI N, Kumada T, Toyoda H, Tada T, et al
    Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
    Dig Dis. 2017;35:521-530.
    PubMed     Text format     Abstract available


  11. YADA N, Tamaki N, Koizumi Y, Hirooka M, et al
    Diagnosis of Fibrosis and Activity by a Combined Use of Strain and Shear Wave Imaging in Patients with Liver Disease.
    Dig Dis. 2017;35:515-520.
    PubMed     Text format     Abstract available


    June 2016
  12. FITZ JG
    Hepatology after Hepatitis C.
    Dig Dis. 2016;34:603-606.
    PubMed     Text format     Abstract available


    January 2016
  13. GERBES AL
    Liver Cirrhosis and Kidney.
    Dig Dis. 2016;34:387-90.
    PubMed     Text format     Abstract available


  14. GARCIA-TSAO G
    Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis.
    Dig Dis. 2016;34:382-6.
    PubMed     Text format     Abstract available


  15. SAFFIOTI F, Pinzani M
    Development and Regression of Cirrhosis.
    Dig Dis. 2016;34:374-81.
    PubMed     Text format     Abstract available


  16. CHISHINA H, Hagiwara S, Nishida N, Ueshima K, et al
    Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Dig Dis. 2016;34:659-664.
    PubMed     Text format     Abstract available


  17. SCORLETTI E, Byrne CD
    Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.
    Dig Dis. 2016;34 Suppl 1:11-8.
    PubMed     Text format     Abstract available


  18. MAHLI A, Hellerbrand C
    Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:32-9.
    PubMed     Text format     Abstract available


  19. DE ALWIS NM, Anstee QM, Day CP
    How to Diagnose Nonalcoholic Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:19-26.
    PubMed     Text format     Abstract available


  20. YADA N, Sakurai T, Minami T, Arizumi T, et al
    Prospective Risk Analysis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C by Ultrasound Strain Elastography.
    Dig Dis. 2016;34:650-653.
    PubMed     Text format     Abstract available


  21. WU T, Wang P, Zhang T, Zheng J, et al
    Comparison of Two-Dimensional Shear Wave Elastography and Real-Time Tissue Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B.
    Dig Dis. 2016;34:640-649.
    PubMed     Text format     Abstract available


  22. NISHIDA N, Kono M, Minami T, Chishina H, et al
    Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2.
    Dig Dis. 2016;34:632-639.
    PubMed     Text format     Abstract available


  23. SUGIMOTO K, Kim SK, Kim SR, Kobayashi M, et al
    Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2.
    Dig Dis. 2016;34:627-631.
    PubMed     Text format     Abstract available


  24. HAGIWARA S, Nishida N, Watanabe T, Sakurai T, et al
    Outcome of Asunaprevir/Daclatasvir Combination Therapy for Chronic Liver Disease Type C.
    Dig Dis. 2016;34:620-626.
    PubMed     Text format     Abstract available


  25. GALLE PR
    Extended Abstract: Management of Liver Cancer.
    Dig Dis. 2016;34:438-9.
    PubMed     Text format     Abstract available


  26. WEISKIRCHEN R, Tacke F
    Liver Fibrosis: From Pathogenesis to Novel Therapies.
    Dig Dis. 2016;34:410-22.
    PubMed     Text format     Abstract available


  27. CHAZOUILLERES O
    Novel Aspects in the Management of Cholestatic Liver Diseases.
    Dig Dis. 2016;34:340-6.
    PubMed     Text format     Abstract available


  28. WEILER-NORMANN C, Lohse AW
    Variant Syndromes of Autoimmune Liver Diseases: Classification, Diagnosis and Management.
    Dig Dis. 2016;34:334-9.
    PubMed     Text format     Abstract available


  29. ARNDTZ K, Hirschfield GM
    The Pathogenesis of Autoimmune Liver Disease.
    Dig Dis. 2016;34:327-33.
    PubMed     Text format     Abstract available


  30. DALTON HR, Webb GW, Norton BC, Woolson KL, et al
    Hepatitis E Virus: Time to Change the Textbooks.
    Dig Dis. 2016;34:308-16.
    PubMed     Text format     Abstract available


  31. BLUM HE
    History and Global Burden of Viral Hepatitis.
    Dig Dis. 2016;34:293-302.
    PubMed     Text format     Abstract available


  32. KOYAMA Y, Xu J, Liu X, Brenner DA, et al
    New Developments on the Treatment of Liver Fibrosis.
    Dig Dis. 2016;34:589-96.
    PubMed     Text format     Abstract available


    October 2015
  33. PISCAGLIA F, Iavarone M, Galassi M, Vavassori S, et al
    Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging.
    Dig Dis. 2015;33:735-744.
    PubMed     Text format     Abstract available


    September 2015
  34. SASAKI M, Nakanuma Y
    Serum Amyloid A-Positive Hepatocellular Neoplasm: A New Type of Tumor Arising in Patients with Advanced Alcoholic Disease.
    Dig Dis. 2015;33:648-654.
    PubMed     Text format     Abstract available


  35. YOPP AC, Choti MA
    Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?
    Dig Dis. 2015;33:642-647.
    PubMed     Text format     Abstract available


    January 2015
  36. RIDLON JM, Kang DJ, Hylemon PB, Bajaj JS, et al
    Gut microbiota, cirrhosis, and alcohol regulate bile Acid metabolism in the gut.
    Dig Dis. 2015;33:338-45.
    PubMed     Text format     Abstract available


  37. BAILLY F, Pradat P, Virlogeux V, Zoulim F, et al
    Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Dig Dis. 2015;33:613-23.
    PubMed     Text format     Abstract available


  38. BOETTLER T, Thimme R
    Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
    Dig Dis. 2015;33:608-12.
    PubMed     Text format     Abstract available


  39. TRAUSSNIGG S, Kienbacher C, Halilbasic E, Rechling C, et al
    Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Dig Dis. 2015;33:598-607.
    PubMed     Text format     Abstract available


  40. WONG F
    Definition and Diagnosis of Acute Kidney Injury in Cirrhosis.
    Dig Dis. 2015;33:539-47.
    PubMed     Text format     Abstract available


  41. SOLA E, Gines P
    Challenges and Management of Liver Cirrhosis: Pathophysiology of Renal Dysfunction in Cirrhosis.
    Dig Dis. 2015;33:534-8.
    PubMed     Text format     Abstract available


  42. PARES A
    Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
    Dig Dis. 2015;33 Suppl 2:125-33.
    PubMed     Text format     Abstract available


  43. JOPSON L, Jones DE
    Fatigue in Primary Biliary Cirrhosis: Prevalence, Pathogenesis and Management.
    Dig Dis. 2015;33 Suppl 2:109-14.
    PubMed     Text format     Abstract available


  44. CORRIGAN M, Hirschfield GM
    Aspects of the Pathophysiology of Primary Biliary Cirrhosis.
    Dig Dis. 2015;33 Suppl 2:102-8.
    PubMed     Text format     Abstract available


  45. SANYAL AJ
    Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
    Dig Dis. 2015;33:426-32.
    PubMed     Text format     Abstract available


  46. STEIB CJ, Schewe J, Gerbes AL
    Infection as a Trigger for Portal Hypertension.
    Dig Dis. 2015;33:570-6.
    PubMed     Text format     Abstract available


  47. DIREKZE S, Jalan R
    Diagnosis and Treatment of Low-Grade Hepatic Encephalopathy.
    Dig Dis. 2015;33:562-9.
    PubMed     Text format     Abstract available


  48. CAVALLIN M, Fasolato S, Marenco S, Piano S, et al
    The Treatment of Hepatorenal Syndrome.
    Dig Dis. 2015;33:548-54.
    PubMed     Text format     Abstract available


  49. ABRALDES JG, Tandon P
    Therapies: Drugs, Scopes and Transjugular Intrahepatic Portosystemic Shunt - When and How?
    Dig Dis. 2015;33:524-33.
    PubMed     Text format     Abstract available


  50. FRIEDMAN SL
    Hepatic Fibrosis: Emerging Therapies.
    Dig Dis. 2015;33:504-7.
    PubMed     Text format     Abstract available


  51. HERKEL J
    Regulatory T Cells in Hepatic Immune Tolerance and Autoimmune Liver Diseases.
    Dig Dis. 2015;33 Suppl 2:70-4.
    PubMed     Text format     Abstract available


  52. VAN BUUREN HR, Lammers WJ, Harms MH, Hansen BE, et al
    Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis.
    Dig Dis. 2015;33 Suppl 2:118-24.
    PubMed     Text format     Abstract available


  53. POUPON R
    Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis.
    Dig Dis. 2015;33 Suppl 2:115-7.
    PubMed     Text format     Abstract available


    January 2014
  54. WU T, Ren J, Cong SZ, Meng FK, et al
    Accuracy of real-time tissue elastography for the evaluation of hepatic fibrosis in patients with chronic hepatitis B: a prospective multicenter study.
    Dig Dis. 2014;32:791-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: